Switch theme
Sign up to access all valuation multiples
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
2010
23
LTM Revenue $4.7M
Last FY EBITDA -$72.1M
$105M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Outlook Therapeutics has a last 12-month revenue (LTM) of $4.7M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Outlook Therapeutics achieved revenue of n/a and an EBITDA of -$72.1M.
Outlook Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Outlook Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $4.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$72.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$61.8M | XXX | -$71.7M | XXX | XXX | XXX |
| EBIT Margin | -1327% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$56.2M | XXX | -$75.4M | XXX | XXX | XXX |
| Net Margin | -1207% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $14.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Outlook Therapeutics's stock price is $2.
Outlook Therapeutics has current market cap of $79.1M, and EV of $105M.
See Outlook Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $105M | $79.1M | XXX | XXX | XXX | XXX | $-2.54 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Outlook Therapeutics has market cap of $79.1M and EV of $105M.
Outlook Therapeutics's trades at n/a EV/Revenue multiple, and -1.7x EV/EBITDA.
Equity research analysts estimate Outlook Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Outlook Therapeutics has a P/E ratio of -1.4x.
See valuation multiples for Outlook Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $79.1M | XXX | $79.1M | XXX | XXX | XXX |
| EV (current) | $105M | XXX | $105M | XXX | XXX | XXX |
| EV/Revenue | 22.5x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.7x | XXX | XXX | XXX |
| EV/EBIT | -1.7x | XXX | -1.5x | XXX | XXX | XXX |
| EV/Gross Profit | 26.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.4x | XXX | -1.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOutlook Therapeutics's last 12 month revenue growth is 455%
Outlook Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $3.1M for the same period.
Outlook Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Outlook Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Outlook Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 455% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Outlook Therapeutics acquired XXX companies to date.
Last acquisition by Outlook Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Outlook Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Outlook Therapeutics founded? | Outlook Therapeutics was founded in 2010. |
| Where is Outlook Therapeutics headquartered? | Outlook Therapeutics is headquartered in United States of America. |
| How many employees does Outlook Therapeutics have? | As of today, Outlook Therapeutics has 23 employees. |
| Who is the CEO of Outlook Therapeutics? | Outlook Therapeutics's CEO is Mr. Lawrence A. Kenyon. |
| Is Outlook Therapeutics publicy listed? | Yes, Outlook Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Outlook Therapeutics? | Outlook Therapeutics trades under OTLK ticker. |
| When did Outlook Therapeutics go public? | Outlook Therapeutics went public in 2016. |
| Who are competitors of Outlook Therapeutics? | Similar companies to Outlook Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Outlook Therapeutics? | Outlook Therapeutics's current market cap is $79.1M |
| What is the current revenue of Outlook Therapeutics? | Outlook Therapeutics's last 12 months revenue is $4.7M. |
| What is the current revenue growth of Outlook Therapeutics? | Outlook Therapeutics revenue growth (NTM/LTM) is 455%. |
| What is the current EV/Revenue multiple of Outlook Therapeutics? | Current revenue multiple of Outlook Therapeutics is 22.5x. |
| Is Outlook Therapeutics profitable? | Yes, Outlook Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
